OraSure Technologies is a diagnostic company that develops, manufactures, and distributes rapid point-of-care tests for infectious diseases and sample collection systems for genomic and clinical testing. The company operates two business segments: diagnostics products including oral fluid-based HIV tests, hepatitis C tests, sickle cell disease tests, and COVID-19 rapid tests sold to professional markets such as hospitals and public health organizations as well as to consumers through retail channels; and sample management solutions comprising proprietary collection and stabilization systems for DNA, RNA, and specialty samples sold to commercial genetics providers, pharmaceutical companies, and academic research institutions. The company generates revenue primarily from product sales across professional diagnostic settings, over-the-counter consumer diagnostics, and genomic sample collection products, competing on the basis of ease of use, proprietary technology, regulatory approvals including FDA clearance and WHO prequalification, and established distribution networks serving both U.S. and international markets.